Eli Lilly and Company
Swiss ExchangeTotal Valuation
Eli Lilly and Company carries a market capitalization of 689.60B, placing it among publicly traded companies globally. Its enterprise value stands at 856.06B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 689.60B |
| Enterprise Value | 856.06B |
Share Statistics
Eli Lilly and Company currently has 893.50M shares outstanding.
| Shares Outstanding | 893.50M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Eli Lilly and Company trades at a trailing price-to-earnings ratio of 32.36. The price-to-sales ratio is 11.32, and the price-to-book ratio stands at 27.17.
| PE Ratio | 32.36 |
| PS Ratio | 11.32 |
| PB Ratio | 27.17 |
| P/TBV Ratio | 46.23 |
| P/FCF Ratio | 26.82 |
| P/OCF Ratio | 39.94 |
Enterprise Valuation
On an enterprise value basis, Eli Lilly and Company trades at an EV/EBITDA multiple of 23.64 and an EV/FCF ratio of 27.67. The EV/Sales ratio of 11.85 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 25.05 provides insight into valuation relative to core operating earnings.
| EV / Sales | 11.85 |
| EV / EBITDA | 23.64 |
| EV / EBIT | 25.05 |
| EV / FCF | 27.67 |
Financial Position
Eli Lilly and Company maintains a current ratio of 1.50, meaning it holds 1.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 139.02, indicating elevated leverage, while an interest coverage ratio of 84.50 demonstrates strong ability to service its debt obligations.
| Current Ratio | 1.50 |
| Quick Ratio | 0.72 |
| Debt / Equity | 139.02 |
| Debt / EBITDA | 1.20 |
| Interest Coverage | 84.50 |
Financial Efficiency
Eli Lilly and Company posts a return on equity of 110.39 and a return on invested capital of 41.09.
| Return on Equity (ROE) | 110.39 |
| Return on Assets (ROA) | 24.54 |
| Return on Invested Capital (ROIC) | 41.09 |
| Return on Capital Employed (ROCE) | 40.11 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 1.04 |
Taxes
Over the trailing twelve months, Eli Lilly and Company has paid 5.85B in income taxes, reflecting an effective tax rate of 18.79.
| Income Tax | 5.85B |
| Effective Tax Rate | 18.79 |
Stock Price Statistics
Eli Lilly and Company's stock has gained approximately 45.52846% over the past 52 weeks. The 50-day moving average sits at 748.80, while the 200-day moving average is 744.68.
| Beta (5Y) | N/A |
| 52-Week Price Change | 45.52846% |
| 50-Day Moving Average | 748.80 |
| 200-Day Moving Average | 744.68 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Eli Lilly and Company generated 72.25B in revenue and converted that into 25.28B in net income, yielding earnings per share of 28.14. EBITDA reached 36.22B, while operating income came in at 34.17B.
| Revenue | 72.25B |
| Gross Profit | 59.84B |
| Operating Income | 34.17B |
| Pretax Income | 31.13B |
| Net Income | 25.28B |
| EBITDA | 36.22B |
| EBIT | 34.17B |
| Earnings Per Share (EPS) | 28.14 |
Balance Sheet
Eli Lilly and Company holds 5.28B in cash and equivalents against 43.37B in total debt, resulting in a net debt position of 38.09B. Total book value stands at 30.10B, with working capital of 18.20B providing operational flexibility.
| Cash & Cash Equivalents | 5.28B |
| Total Debt | 43.37B |
| Net Debt | 38.09B |
| Equity (Book Value) | 30.10B |
| Book Value Per Share | 33.62 |
| Working Capital | 18.20B |
Cash Flow
Eli Lilly and Company produced 20.48B in operating cash flow over the past twelve months. After subtracting -10.11B in capital expenditures, free cash flow totaled 10.37B - equivalent to 11.58 per share.
| Operating Cash Flow | 20.48B |
| Capital Expenditures | -10.11B |
| Free Cash Flow | 10.37B |
| FCF Per Share | 11.58 |
Margins
Eli Lilly and Company operates with a gross margin of 82.83, reflecting its pricing power and cost economics. The operating margin of 47.30 and net profit margin of 34.99 provide insight into operational efficiency.
| Gross Margin | 82.83 |
| Operating Margin | 47.30 |
| Pretax Margin | 43.08 |
| Profit Margin | 34.99 |
| EBITDA Margin | 50.13 |
Dividends & Yields
The company's payout ratio of 22.10 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 6.24 |
| Dividend Yield | N/A |
| Payout Ratio | 22.10 |
| Shareholder Yield | 0.86 |
| FCF Yield | 3.73 |
Scores
Eli Lilly and Company posts an Altman Z-Score of 8.16, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 8.16 |